title: Frontline therapy of multiple myeloma.
abstract: In the past decade, one of the major advances in the management of patients with symptomatic newly diagnosed multiple myeloma has been the introduction of novel agents, thalidomide, bortezomib, and lenalidomide, as part of frontline treatment in both transplant and nontransplant candidates. These drugs have markedly improved the rate of complete remission, and time to progression, progression-free survival, and overall survival have significantly increased. This article focuses on more recent frontline therapeutic approaches both in older patients, not eligible for high-dose therapy and autologous stem cell transplantation (ASCT), and in younger patients eligible for early ASCT.
authors.affiliation: Department of Hematology, Centre Hospitalier Universitaire de Nantes, Nantes, France;
authors.forename: Philippe
authors.initials: P
authors.lastname: Moreau
authors.affiliation: Service d'Hématologie, Hopital Purpan, Toulouse, France; and.
authors.forename: Michel
authors.initials: M
authors.lastname: Attal
authors.affiliation: Department of Hematology, University Hospital Hurriez, Lille, France.
authors.forename: Thierry
authors.initials: T
authors.lastname: Facon
mesh_terms: D000367:Age Factors; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009101:Multiple Myeloma / Q000628:therapy*; D016896:Treatment Outcome